Document is current

Any future updates will be listed below

Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China

Crossref DOI link: https://doi.org/10.1038/s41598-025-91540-9

Published Online: 2025-03-24

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark